Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib - Trial NCT06120140
Access comprehensive clinical trial information for NCT06120140 through Pure Global AI's free database. This Phase 2 trial is sponsored by Janssen Research & Development, LLC and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 180 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Janssen Research & Development, LLC
Timeline & Enrollment
Phase 2
Mar 08, 2024
Nov 30, 2026
Primary Outcome
Number of Participants With Grade Greater Than or Equal to (=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment
Summary
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce
 incidence of grade greater than or equal to (=) 2 dermatologic adverse events of interest
 (DAEIs) when compared with standard-of-care skin management in participants with locally
 advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated
 non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06120140
Non-Device Trial